Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6458580rdf:typepubmed:Citationlld:pubmed
pubmed-article:6458580lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:6458580lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6458580lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:6458580lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:6458580lifeskim:mentionsumls-concept:C2003905lld:lifeskim
pubmed-article:6458580pubmed:issue9-10lld:pubmed
pubmed-article:6458580pubmed:dateCreated1982-2-22lld:pubmed
pubmed-article:6458580pubmed:abstractTextIn patients with early stages (I, II) of breast cancer we identified a subset of circulating lymphocytes that carry ferritin on their surface. No such lymphocytes were identified in normal women nor in women with benign breast disease. These cells did not form spontaneous rosettes with sheep red blood cells. Further studies revealed that in vitro treatment of the patients' lymphocytes with levamisole resulted n the removal of the surface ferritin and in an increase in the reactivity of the lymphocytes in mixed lymphocyte culture (MLC). Separation of the ferritin-positive lymphocytes from the E-rosetting T cells resulted in an increased reactivity of the patients' T cells in MLC. Readdition of the fraction containing the ferritin-positive cells to a mixed lymphocyte culture resulted in a decrease in the proliferative response of the patients' T lymphocytes. It is suggested that the ferritin-positive lymphocytes in breast cancer patients represent an active suppressor cell subset.lld:pubmed
pubmed-article:6458580pubmed:languageenglld:pubmed
pubmed-article:6458580pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6458580pubmed:citationSubsetIMlld:pubmed
pubmed-article:6458580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6458580pubmed:statusMEDLINElld:pubmed
pubmed-article:6458580pubmed:issn0021-2180lld:pubmed
pubmed-article:6458580pubmed:authorpubmed-author:MoronWWlld:pubmed
pubmed-article:6458580pubmed:authorpubmed-author:KupferBBlld:pubmed
pubmed-article:6458580pubmed:issnTypePrintlld:pubmed
pubmed-article:6458580pubmed:volume17lld:pubmed
pubmed-article:6458580pubmed:ownerNLMlld:pubmed
pubmed-article:6458580pubmed:authorsCompleteYlld:pubmed
pubmed-article:6458580pubmed:pagination879-81lld:pubmed
pubmed-article:6458580pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:meshHeadingpubmed-meshheading:6458580-...lld:pubmed
pubmed-article:6458580pubmed:articleTitleSuppressor cel activity of ferritin-bearing lymphocytes in patients with breast cancer.lld:pubmed
pubmed-article:6458580pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6458580pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6458580lld:pubmed